← back to search

Kristina Schwamborn

Technical University of Munich · DE
Area of research
Spectroscopy · Surgery
Research interest
Research interests include Medicine, Mass spectrometry imaging, Mass spectrometry, Immunohistochemistry, Internal medicine, and Computer science.
h-index
citations
686
works
24
NIH funding
primary concept
email

Recent publications

Large language models-enabled digital twins for precision medicine in rare gynecological tumors
npj Digital Medicine 2025cited by 19position: middledoi
Expert-Guided Large Language Models for Clinical Decision Support in Precision Oncology
JCO Precision Oncology 2024cited by 45position: middledoi
Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution
European Urology 2023cited by 16position: middledoi
Heterogeneity of prostate-specific membrane antigen (PSMA) and PSMA-ligand uptake detection combining autoradiography and postoperative pathology in primary prostate cancer
EJNMMI Research 2023cited by 9position: middledoi
Spatial immunophenotypes of distant metastases and response to immune checkpoint inhibition.
Journal of Clinical Oncology 2023cited by 0position: middledoi
Data from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
2023cited by 0position: middledoi
Data from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
2023cited by 0position: middledoi
Spatial Immunephenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas Predict Response to Immune Checkpoint Inhibition
European Urology 2022cited by 21position: middledoi
MALDI Mass Spectrometry Imaging for the Distinction of Adenocarcinomas of the Pancreas and Biliary Tree
Molecules 2022cited by 16position: lastdoi
Ncald as a Potential Predictive Biomarker for the Efficacy of Platinum-Based Chemotherapy in Ovarian Cancer
Biomarkers in Medicine 2022cited by 1position: middledoi
Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer
The Breast 2021cited by 35position: middledoi
Neuroendocrine Differentiation in Conventional Colorectal Adenocarcinomas: Incidental Finding or Prognostic Biomarker?
Cancers 2021cited by 20position: middledoi
The Impact of Histological Annotations for Accurate Tissue Classification Using Mass Spectrometry Imaging
Metabolites 2021cited by 11position: lastdoi
Mass Spectrometry Imaging for Reliable and Fast Classification of Non-Small Cell Lung Cancer Subtypes
Cancers 2020cited by 23position: middledoi
Mass Spectrometry Imaging Differentiates Chromophobe Renal Cell Carcinoma and Renal Oncocytoma with High Accuracy
Journal of Cancer 2020cited by 10position: middledoi
Status der Verfügbarkeit und Anwendung von „next generation sequencing“ (NGS) beim Harnblasenkarzinom – eine Umfrage in der Arbeitsgemeinschaft Uropathologie
Der Urologe 2019cited by 3position: middledoi
Combined Immunohistochemistry after Mass Spectrometry Imaging for Superior Spatial Information
PROTEOMICS - CLINICAL APPLICATIONS 2018cited by 25position: middledoi
Digital PCR After MALDI–Mass Spectrometry Imaging to Combine Proteomic Mapping and Identification of Activating Mutations in Pulmonary Adenocarcinoma
PROTEOMICS - CLINICAL APPLICATIONS 2018cited by 21position: middledoi
Identification of MALDI Imaging Proteolytic Peptides Using LC‐MS/MS‐Based Biomarker Discovery Data: A Proof of Concept
PROTEOMICS - CLINICAL APPLICATIONS 2018cited by 21position: middledoi
In MALDI–Mass Spectrometry Imaging on Formalin‐Fixed Paraffin‐Embedded Tissue Specimen Section Thickness Significantly Influences <i>m/z</i> Peak Intensity
PROTEOMICS - CLINICAL APPLICATIONS 2018cited by 21position: middledoi
Proteomics in Pathology
PROTEOMICS 2017cited by 19position: middledoi
Reliable Entity Subtyping in Non-small Cell Lung Cancer by Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry on Formalin-fixed Paraffin-embedded Tissue Specimens
Molecular & Cellular Proteomics 2016cited by 88position: middledoi
In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma
EMBO Molecular Medicine 2015cited by 212position: middledoi
MALDI MS imaging as a powerful tool for investigating synovial tissue
Scandinavian Journal of Rheumatology 2012cited by 50position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Wilko Weichert · German Cancer Research Center15 papers (2016–2023)Mark Kriegsmann · Zentrum für Pathologie und Zytodiagnostik9 papers (2012–2020) · 8 papers (2016–2020)Peter Schirmacher · Kliniken Essen-Mitte7 papers (2016–2020)Jörg Kriegsmann · Charité - Universitätsmedizin Berlin7 papers (2012–2020)Katharina Kriegsmann · German Center for Lung Research7 papers (2017–2020)Albrecht Stenzinger · Chirurgische Universitätsklinik Heidelberg6 papers (2016–2020)Christiane Zgorzelski · University Hospital Heidelberg5 papers (2018–2020)Rémi Longuespée · Institut National des Sciences Appliquées de Strasbourg5 papers (2017–2018)Daniel Kazdal · Heidelberg University5 papers (2017–2018)Thomas Horn · Harvard University4 papers (2022–2023)Margaux Fresnais · Heidelberg University4 papers (2018–2018)Franziska Erlmeier · Technical University of Munich4 papers (2020–2023)Marion Kiechle · Klinik für Frauenheilkunde4 papers (2021–2025)Arne Warth · Heidelberg University4 papers (2016–2020)Manuel Ritter · University Hospital Heidelberg3 papers (2022–2023)Sebastian Lange · Heidelberg University3 papers (2021–2025)Christine Bollwein · Technical University of Munich3 papers (2018–2022)Philipp Erben · Ludwig-Maximilians-Universität München3 papers (2022–2023)Bernd Wullich · DKFZ-ZMBH Alliance3 papers (2022–2023)